Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials
Open accessAbstract
BACKGROUND: Considering the increasing prevalence of obesity/overweight, its treatment or prevention with new interventions can greatly help health and reduce its adverse effects in people. One of these new interventions is investigating the effect of Survodutide as a dual agonist of glucagon and GLP-1 receptors, which seems to be able to influence weight loss processes in different ways. In this study, we investigated the effect of injectable Survodutide on weight loss. METHODS: In order to identify all randomized controlled trials that investigated the effects of Survodutide on factores related to obesity, a systematic search was conducted in the original databases using predefined keywords until August 2024. The pooled weighted mean difference and 95% confidence intervals were computed using the random-effects model. RESULTS: = 99.5%) following the Survodutide injection compared to the control group. Subgroup analysis reveals that longer interventions (more than 16 weeks) and higher doses (more than 2 mg/week) of Survodutide are associated with more significant reductions in weight and WC. These results were also observed in the meta-regression analysis. CONCLUSIONS: The results of this meta-analysis show that Survodutide is effective in reducing weight, BMI and waist circumference, especially with longer interventions and higher doses.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Survodutide demonstrated significant weight reduction in our review, which corresponds with the outcomes described by Wan et al.
“Survodutide demonstrated significant weight reduction in our review, which corresponds with the outcomes described by Wan et al.”
From Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials (2026) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · see citing works
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · see citing works
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · see citing works
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223 · see citing works
Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854 · see citing works
Estimating the mean and variance from the median, range, and the size of a sample
Hozo, S. P., Djulbegovic, B., & Hozo, I. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-13 · Cited by 9,062 · see citing works
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · see citing works
The Epidemiology of Obesity: A Big Picture
Hruby, A., & Hu, F. B. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0243-x · Cited by 3,006 · see citing works
Assessing risk of bias in a randomized trial
Higgins, J. P., Savović, J., Page, M. J., Elbers, R. G., & Sterne, J. A. (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch8 · Cited by 1,765 · see citing works
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · see citing works
Weight and Metabolic Outcomes 12 Years after Gastric Bypass
Adams, T. D., Davidson, L. E., Litwin, S. E., Kim, J., Kolotkin, R. L., Nanjee, M. N., Gutierrez, J. M., Frogley, S. J., Ibele, A. R., Brinton, E. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700459 · Cited by 956 · see citing works
Comparative Effectiveness of Weight-Loss Interventions in Clinical Practice
Appel, L. J., Clark, J. M., Yeh, H.-C., Wang, N.-Y., Coughlin, J. W., Daumit, G., Miller, E. R., Dalcin, A., Jerome, G. J., Geller, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108660 · Cited by 783 · see citing works
Lifestyle modification approaches for the treatment of obesity in adults.
Wadden, T. A., Tronieri, J. S., & Butryn, M. L. (2020) · American Psychologist · doi:10.1037/amp0000517 · Cited by 661 · see citing works
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577 · see citing works
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401755 · Cited by 528 · see citing works
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462 · see citing works
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435 · see citing works
Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363 · see citing works
Schwingshackl, L., Knüppel, S., Schwedhelm, C., Hoffmann, G., Missbach, B., Stelmach-Mardas, M., Dietrich, S., Eichelmann, F., Kontopanteils, E., Iqbal, K., et al. (2016) · Advances in Nutrition · doi:10.3945/an.116.013052 · Cited by 360 · see citing works
Random-Effects Meta-Analyses Are Not Always Conservative
Poole, C., & Greenland, S. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010035 · Cited by 338 · see citing works
Dynamic lipidome alterations associated with human health, disease and ageing
Hornburg, D., Wu, S., Moqri, M., Zhou, X., Contrepois, K., Bararpour, N., Traber, G. M., Su, B., Metwally, A. A., Avina, M., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00880-1 · Cited by 266 · see citing works
le Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A., & Hennige, A. M. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00356-x · Cited by 237 · see citing works
Williams, R. L., Wood, L. G., Collins, C. E., & Callister, R. (2014) · Obesity Reviews · doi:10.1111/obr.12241 · Cited by 236 · see citing works
Healthy strategies for successful weight loss and weight maintenance: a systematic review
Ramage, S. M., Farmer, A. P., Eccles, K. A., & McCargar, L. (2013) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2013-0026 · Cited by 210 · see citing works
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
Salem, V., Izzi‐Engbeaya, C., Coello, C., Thomas, D. B., Chambers, E. S., Comninos, A. N., Buckley, A., Win, Z., Al‐Nahhas, A., Rabiner, E. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12585 · Cited by 167 · see citing works
The metabolomics of human aging: Advances, challenges, and opportunities
Panyard, D. J., Yu, B., & Snyder, M. P. (2022) · Science Advances · doi:10.1126/sciadv.add6155 · Cited by 155 · see citing works
Zimmermann, T., Thomas, L., Baader-Pagler, T., Haebel, P., Simon, E., Reindl, W., Bajrami, B., Rist, W., Uphues, I., Drucker, D. J., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101633 · Cited by 149 · see citing works
Blüher, M., Rosenstock, J., Hoefler, J., Manuel, R., & Hennige, A. M. (2024) · Diabetologia · doi:10.1007/s00125-023-06053-9 · Cited by 138 · see citing works
Machado, A. M., Guimarães, N. S., Bocardi, V. B., da Silva, T. P. R., Carmo, A. S. D., Menezes, M. C. D., & Duarte, C. K. (2022) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2022.03.020 · Cited by 109 · see citing works
Self-citationOxyntomodulin: actions and role in diabetes
Holst, J. J., Albrechtsen, N. J. W., Gabe, M. B. N., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.09.018 · Cited by 86 · see citing works
Jungnik, A., Arrubla Martinez, J., Plum‐Mörschel, L., Kapitza, C., Lamers, D., Thamer, C., Schölch, C., Desch, M., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14948 · Cited by 63 · see citing works
Pharmacotherapy for obesity: moving towards efficacy improvement
Coutinho, W. F., & Halpern, B. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01233-4 · Cited by 62 · see citing works
HETEROGENEITY IN META-ANALYSIS
Borenstein, M. (2019) · Russell Sage Foundation eBooks · doi:10.7758/9781610448864.23 · Cited by 57 · see citing works
Reis, M. G., Moreira, L. F. G. G., CARVALHO, L. S. V. D. A., de Castro, C. T., Vieira, R. A. L., & Guimarães, N. S. (2023) · Obesity Medicine · doi:10.1016/j.obmed.2023.100528 · Cited by 46 · see citing works
Self-citationIren Jaison, K., Asharaf, H., Thimothy, G., George, S., Jose, J., Paily, R., Josey, J., Sajna, S. J., & Radhakrishnan, R. (2023) · Obesity Medicine · doi:10.1016/j.obmed.2023.100530 · Cited by 35 · see citing works
Hayashi, Y. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13315 · Cited by 28 · see citing works
Yazawa, R., Ishida, M., Balavarca, Y., & Hennige, A. M. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15064 · Cited by 26 · see citing works
Perspectives in weight control in diabetes - survodutide
Klein, T., Augustin, R., & Hennige, A. M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110779 · Cited by 25 · see citing works
Mäkinen, V., & Ala‐Korpela, M. (2024) · International Journal of Epidemiology · doi:10.1093/ije/dyae055 · Cited by 20 · see citing works
Edwards‐Hampton, S. A., & Ard, J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15819 · Cited by 17 · see citing works
Li, P., Huang, Y., & Wong, A. (2023) · British Journal Of Nutrition · doi:10.1017/s0007114523001940 · Cited by 11 · see citing works
Chu, P., Yu, Y., Pan, Y., Dai, Y.-H., Yang, J., Huang, K., & Wu, Y. (2024) · Metabolites · doi:10.3390/metabo14020129 · Cited by 9 · see citing works
Yousif, A. B., Mudarres, M. F., Yousef, M. F., Badawi, A., & Hassan, E. A. (2024) · Yemen Journal of Medicine · doi:10.18231/j.yjom.2024.005 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 13 · see citing works
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 9 · see citing works
Stachteas, P., Nasoufidou, A., Karakasis, P., Koiliari, M., Karagiannidis, E., Koufakis, T., Fragakis, N., & Patoulias, D. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39691 · Cited by 9 · see citing works
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8 · see citing works
Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Abreu, E. S., Noureddin, M., Takahashi, H., Schattenberg, J. M., & Abdelmalek, M. F. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.004 · Cited by 4 · see citing works
Abulehia, A., Ayesh, H., Ayesh, O., Jaber, D., Asad, T., Itbaisha, A., Abugharbieh, H., Gharbia, R., Abu‐Hilal, L. H., & Leon, B. G. C. (2026) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70187 · Cited by 2 · see citing works
Xiao, Y., Yu, S. P., Zhang, Y., Chen, J., Yan-qun, L., Liu, X., Sun, C., & Deng, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70105 · Cited by 2 · see citing works
Piguet, C. E. M., Nucci, R., & Beaudry, J. L. (2026) · The Journal of Physiology · doi:10.1113/jp291081 · Cited by 1 · see citing works
Chen, Z., Zhou, Y., Li, G., MUTHANNA, A., d’Arqom, A., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02110-3
- Authors
- Wan, H., Xu, N., Wang, L., Liu, Y., Fatahi, S., Sohouli, M. H., & Guimarães, N. S.
- Affiliations
- Nanjing General Hospital of Nanjing Military Command (CN)
- Shahid Beheshti University (IR)
- Children's Medical Center (IR)
- Corresponding author
- Sohouli, Mohammad Hassan
- Venue
- Diabetology & Metabolic Syndrome
- Published
- 2024-11-06
- Volume
- 16
- Issue
- 1
- Pages
- 264-264
- ISSN
- 1758-5996 (ISSN-L)
- PMC
- PMC11542446
- OpenAlex
- W4404105365
- Cited by
- 8
- References
- 44
- Citations by year
- 2026: 4 · 2025: 4
- FWCI
- 0.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetology & Metabolic Syndrome (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- survodutide, glucagon receptor agonist, GLP-1 receptor agonists, dual agonist, weight loss, obesity, overweight, body mass index, waist circumference, treatment duration, drug dosing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
